Four approvals, a first-ever in-vivo CRISPR filing accepted with Priority Review, two high-profile pivotal misses, and roughly $1.6 billion of confirmed private financing — a week where mechanism mattered less than manufacturing, endpoint choice…
Six approvals, a pivotal cardiovascular-outcomes miss, two paused autoimmune cell-therapy programs, and roughly $6.9 billion of headline dealmaking — this week’s signals only counted once verified against a primary source. Weekly Biotech Signal Review…
Biotech had an approval week that tested whether comparative human evidence still beats platform storytelling. Broad active-state RAS inhibition crossed from thesis to approved medicine when the FDA cleared Rasonque after a 500-patient randomized…
Biotech had an approval week. Ultragenyx’s first-ever gene therapy for glycogen storage disease type Ia, Regeneron’s second-ever disease-modifying therapy for fibrodysplasia ossificans progressiva, and Amylyx’s blowout Phase 3 win in post-bariatric hypoglycemia landed within…
Biotech’s week traded distress for discipline: Sangamo’s bankruptcy auction let PTC Therapeutics pick up a near-approval Fabry gene therapy for a fraction of its original value, Bristol Myers Squibb banked the first-ever approval of…
Weekly Biotech Signal Review — Week of July 26-31, 2026.
